SAGE Stock Price, Chart, Stats & News
Sage Therapeutics, Inc. (SAGE) does not currently pay a dividend.
SAGE chart
Price history is unavailable
We don't have enough price data for SAGE to draw a chart yet.
Fundamentals
Gross margin | 89.54% |
Operating margin | -461.33% |
Pretax margin | -427.77% |
Net margin | -427.77% |
Effective tax rate | – |
ROA | -71.22% |
ROE | -67.10% |
D/E | 0.03x |
Interest coverage ratio | – |
SAGE valuation
P/E | – |
P/S | 7.74x |
P/B | 1.47x |
P/CF | -1.88x |
P/FCF | -1.88x |
P/OCF | -1.88x |
PEG | -0.12x |
EV multiple | -1.99x |
About
Sage Therapeutics, Inc. functions as a biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of therapeutic agents aimed at central nervous system (CNS) conditions. Its primary medication is ZULRESSO, an intravenous form of brexanolone, prescribed for the treatment of postpartum depression (PPD) in adult patients. The company's advanced pipeline includes zuranolone, a neuroactive steroid, which is presently undergoing Phase III clinical trials for several disorders, such as PPD, major depressive disorders, treatment-resistant depression, generalized anxiety disorders, and bipolar depression.
Similar securities
Based on sector and market capitalization
